Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Shenmiao Yang; Neil E. Kay; Min Shi; Curtis A. Hanson; Robert Peter Gale

doi:10.1038/s41375-022-01699-7

Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Shenmiao Yang, Neil E. Kay, Min Shi, Curtis A. Hanson, Robert Peter Gale

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2743-2747
Number of pages	5
Journal	Leukemia
Volume	36
Issue number	11
DOIs	https://doi.org/10.1038/s41375-022-01699-7
State	Published - Nov 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-022-01699-7

Cite this

@article{c2936f6db96f431984d67af783061841,

title = "Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?",

author = "Shenmiao Yang and Kay, {Neil E.} and Min Shi and Hanson, {Curtis A.} and Gale, {Robert Peter}",

note = "Funding Information: RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme and the Ministry of Science and Technology of China (84000-51200002). Funding Information: NEK, Advisory Board for: AbbVie, Astra Zeneca, Beigene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for: Agios Pharm, AstraZeneca, BMS –Celgene, Cytomx Therapeutics, Dren Bio Janssen, Morpho-sys, Rigel. Research funding from: AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. RPG, consultant to NexImmune Inc, Nanexa Pharma, Ascentage Pharma Group, Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; Partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd. ",

year = "2022",

month = nov,

doi = "10.1038/s41375-022-01699-7",

language = "English (US)",

volume = "36",

pages = "2743--2747",

journal = "Leukemia",

issn = "0887-6924",